inclusion criteria: 1. age ≥ 18 years 2. admitted to icu within 48 hours 3. confirmed or highly suspected covid-19 infection 4. acute hypoxemic respiratory failure (pao2 \<70 mmhg or spo2\<90% on room air or tachypnea\>30/min or labored breathing or respiratory distress; need for oxygen flow \>=6l/min) 5. any treatment intended to treat the sars-cov-2 infection in the absence of contraindications (either as a compassionate use or in the context of a clinical trial, i.e remdesivir, lopinavir/ritonavir, favipiravir, hydroxychloroquine and any other new drug with potential activity). non-inclusion criteria: 1. moribund status 2. pregnancy or breastfeeding 3. long term corticotherapy at a dose of 0.5mg/kg/j or higher 4. active and untreated bacterial, fungal or parasitic infection 5. not written informed consent from the patient or a legal representative if appropriate . if absence a legal representative the patient may be included in emergency procedure 6. hypersensitivity to dexamethasone or to any of the excipients 7. not affiliation to the french social security

inclusion criteria: 1. age ≥ 18 years 2. admitted to icu within 48 hours 3. confirmed or highly suspected covid-19 infection 4. acute hypoxemic respiratory failure (pao2 \<70 mmhg or spo2\<90% on room air or tachypnea\>30/min or labored breathing or respiratory distress; need for oxygen flow \>=6l/min) 5. any treatment intended to treat the sars-cov-2 infection in the absence of contraindications (either as a compassionate use or in the context of a clinical trial, i.e remdesivir, lopinavir/ritonavir, favipiravir, hydroxychloroquine and any other new drug with potential activity). non-inclusion criteria: 1. moribund status 2. pregnancy or breastfeeding 3. long term corticotherapy at a dose of 0.5mg/kg/j or higher 4. active and untreated bacterial, fungal or parasitic infection 5. not written informed consent from the patient or a legal representative if appropriate . if absence a legal representative the patient may be included in emergency procedure 6. hypersensitivity to dexamethasone or to any of the excipients 7. not affiliation to the french social security

inclusion criteria: age ≥ 18 years admitted to icu within 48 hours confirmed or highly suspected covid-19 infection acute hypoxemic respiratory failure (pao2 <70 mmhg or spo2<90% on room air or tachypnea>30/min or labored breathing or respiratory distress; need for oxygen flow >=6l/min) any treatment intended to treat the sars-cov-2 infection in the absence of contraindications (either as a compassionate use or in the context of a clinical trial, i.e remdesivir, lopinavir/ritonavir, favipiravir, hydroxychloroquine and any other new drug with potential activity). non-inclusion criteria: moribund status pregnancy or breastfeeding long term corticotherapy at a dose of 0.5mg/kg/j or higher active and untreated bacterial, fungal or parasitic infection not written informed consent from the patient or a legal representative if appropriate . if absence a legal representative the patient may be included in emergency procedure hypersensitivity to dexamethasone or to any of the excipients not affiliation to the french social security

inclusion criteria: age ≥ 18 years admitted to icu within 48 hours confirmed or highly suspected covid-19 infection acute hypoxemic respiratory failure (pao2 <70 mmhg or spo2<90% on room air or tachypnea>30/min or labored breathing or respiratory distress; need for oxygen flow >=6l/min) any treatment intended to treat the sars-cov-2 infection in the absence of contraindications (either as a compassionate use or in the context of a clinical trial, i.e remdesivir, lopinavir/ritonavir, favipiravir, hydroxychloroquine and any other new drug with potential activity). non-inclusion criteria: moribund status pregnancy or breastfeeding long term corticotherapy at a dose of 0.5mg/kg/j or higher active and untreated bacterial, fungal or parasitic infection not written informed consent from the patient or a legal representative if appropriate . if absence a legal representative the patient may be included in emergency procedure hypersensitivity to dexamethasone or to any of the excipients not affiliation to the french social security

inclusion criteria: 1. age ≥ 18 years 2. admitted to icu within 48 hours 3. confirmed or highly suspected covid-19 infection 4. acute hypoxemic respiratory failure (pao2 <70 mmhg or spo2<90% on room air or tachypnea>30/min or labored breathing or respiratory distress; need for oxygen flow >=6l/min) 5. any treatment intended to treat the sars-cov-2 infection in the absence of contraindications (either as a compassionate use or in the context of a clinical trial, i.e remdesivir, lopinavir/ritonavir, favipiravir, hydroxychloroquine and any other new drug with potential activity). non-inclusion criteria: 1. moribund status 2. pregnancy or breastfeeding 3. long term corticotherapy at a dose of 0.5mg/kg/j or higher 4. active and untreated bacterial, fungal or parasitic infection 5. not written informed consent from the patient or a legal representative if appropriate . if absence a legal representative the patient may be included in emergency procedure 6. hypersensitivity to dexamethasone or to any of the excipients 7. not affiliation to the french social security

inclusion criteria: 1. age ≥ 18 years 2. admitted to icu within 48 hours 3. confirmed or highly suspected covid-19 infection 4. acute hypoxemic respiratory failure (pao2 <70 mmhg or spo2<90% on room air or tachypnea>30/min or labored breathing or respiratory distress; need for oxygen flow >=6l/min) 5. any treatment intended to treat the sars-cov-2 infection in the absence of contraindications (either as a compassionate use or in the context of a clinical trial, i.e remdesivir, lopinavir/ritonavir, favipiravir, hydroxychloroquine and any other new drug with potential activity). non-inclusion criteria: 1. moribund status 2. pregnancy or breastfeeding 3. long term corticotherapy at a dose of 0.5mg/kg/j or higher 4. active and untreated bacterial, fungal or parasitic infection 5. not written informed consent from the patient or a legal representative if appropriate . if absence a legal representative the patient may be included in emergency procedure 6. hypersensitivity to dexamethasone or to any of the excipients 7. not affiliation to the french social security

inclusion criteria: 1. age ≥ 18 years 2. admitted to icu within 48 hours 3. confirmed or highly suspected covid-19 infection 4. acute hypoxemic respiratory failure (pao2 <70 mmhg or spo2<90% on room air or tachypnea>30/min or labored breathing or respiratory distress; need for oxygen flow >=6l/min) 5. any treatment intended to treat the sars-cov-2 infection (either as a compassionate use or in the context of a clinical trial, i.e remdesivir, lopinavir/ritonavir, favipiravir, hydroxychloroquine and any other new drug with potential activity).

inclusion criteria: 1. age ≥ 18 years 2. admitted to icu within 48 hours 3. confirmed or highly suspected covid-19 infection 4. acute hypoxemic respiratory failure (pao2 <70 mmhg or spo2<90% on room air or tachypnea>30/min or labored breathing or respiratory distress; need for oxygen flow >=6l/min) 5. any treatment intended to treat the sars-cov-2 infection (either as a compassionate use or in the context of a clinical trial, i.e remdesivir, lopinavir/ritonavir, favipiravir, hydroxychloroquine and any other new drug with potential activity).